热门出版物 - 学术资源搜索

h5 指数:82
h5 中位数:117

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2018-2022 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#2 Obesity
#5 Diabetes

标题/作者	引用次数	年份
COVID‐19 infection may cause ketosis and ketoacidosis J Li, X Wang, J Chen, X Zuo, H Zhang, A Deng Diabetes, Obesity and Metabolism 22 (10), 1935-1941	555	2020
Incretin hormones: Their role in health and disease MA Nauck, JJ Meier Diabetes, Obesity and Metabolism 20, 5-21	534	2018
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton Diabetes, Obesity and Metabolism 20 (3), 479-487	403	2018
Prevalence of co‐morbidities and their association with mortality in patients with COVID‐19: A systematic review and meta‐analysis AK Singh, CL Gillies, R Singh, A Singh, Y Chudasama, B Coles, S Seidu, ... Diabetes, Obesity and Metabolism 22 (10), 1915-1924	376	2020
Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials Y Zhao, L Xu, D Tian, P Xia, H Zheng, L Wang, L Chen Diabetes, Obesity and Metabolism 20 (2), 458-462	287	2018
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review K Khunti, MB Gomes, S Pocock, MV Shestakova, S Pintat, P Fenici, ... Diabetes, Obesity and Metabolism 20 (2), 427-437	275	2018
Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID‐19 H Li, S Tian, T Chen, Z Cui, N Shi, X Zhong, K Qiu, J Zhang, T Zeng, ... Diabetes, Obesity and Metabolism 22 (10), 1897-1906	268	2020
An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines NM Selby, MW Taal Diabetes, Obesity and Metabolism 22, 3-15	247	2020
Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. T Sathish, N Kapoor, Y Cao, RJ Tapp, P Zimmet Diabetes, Obesity & Metabolism 23 (3), 870-874	245	2020
Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease M Shimizu, K Suzuki, K Kato, T Jojima, T Iijima, T Murohisa, M Iijima, ... Diabetes, Obesity and Metabolism 21 (2), 285-292	242	2019
A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials VR Aroda Diabetes, Obesity and Metabolism 20, 22-33	223	2018
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis T Toyama, BL Neuen, M Jun, T Ohkuma, B Neal, MJ Jardine, ... Diabetes, Obesity and Metabolism 21 (5), 1237-1250	214	2019
Identification of barriers to insulin therapy and approaches to overcoming them D Russell‐Jones, F Pouwer, K Khunti Diabetes, Obesity and Metabolism 20 (3), 488-496	212	2018
Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers CCJ Dekkers, S Petrykiv, GD Laverman, DZ Cherney, RT Gansevoort, ... Diabetes, Obesity and Metabolism 20 (8), 1988-1993	204	2018
Effects of an energy‐restricted low‐carbohydrate, high unsaturated fat/low saturated fat diet versus a high‐carbohydrate, low‐fat diet in type 2 diabetes: A 2‐year randomized clinical trial J Tay, CH Thompson, ND Luscombe‐Marsh, TP Wycherley, M Noakes, ... Diabetes, Obesity and Metabolism 20 (4), 858-871	200	2018
Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study F Persson, T Nyström, ME Jørgensen, B Carstensen, HL Gulseth, ... Diabetes, Obesity and Metabolism 20 (2), 344-351	193	2018
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy T Vilsbøll, SC Bain, LA Leiter, I Lingvay, D Matthews, R Simó, IC Helmark, ... Diabetes, Obesity and Metabolism 20 (4), 889-897	191	2018
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D) PB Ryan, JB Buse, MJ Schuemie, F DeFalco, Z Yuan, PE Stang, JA Berlin, ... Diabetes, Obesity and Metabolism 20 (11), 2585-2597	187	2018
Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes (REWIND) trial on the cardiovascular effects of dulaglutide HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... Diabetes, Obesity and Metabolism 20 (1), 42-49	179	2018
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study T Shibuya, N Fushimi, M Kawai, Y Yoshida, H Hachiya, S Ito, H Kawai, ... Diabetes, Obesity and Metabolism 20 (2), 438-442	170	2018

1 - 20

计算机程序会自动估算并确定日期和引用次数。